<p>根据 Alps Advisors Inc.最近向证券交易委员会提交的 13F 表格，该公司在 2023 年第三季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 13.2%。这家机构投资者在季度内额外收购了 128,134 股后，持有辉瑞的股票总数为 1,099,603 股。Alps Advisors Inc.在辉瑞的持股在最近一个季度末的价值为 28,018,000 美元。</p>
<ul>
<li>辉瑞在第四季度业绩上升——但这可能是最重要的催化剂</li>
</ul>
<p>其他对冲基金和机构投资者最近也增加或减少了在该公司的持股。Peak Asset Management LLC 在第二季度将其在辉瑞的持股提高了 1.4%。Peak Asset Management LLC 现在拥有 28,768 股辉瑞的股票，价值为 697,000 美元，此前在上个季度又购买了 402 股。Community Bank &amp; Trust Waco Texas 在第三季度将其在辉瑞的持股提高了 0.6%。Community Bank &amp; Trust Waco Texas 现在拥有 66,841 股辉瑞的股票，价值为 1,703,000 美元，此前在上个季度又购买了 412 股。Able Wealth Management LLC 在第二季度将其在辉瑞的持股提高了 2.0%。Able Wealth Management LLC 现在拥有 21,128 股辉瑞的股票，价值为 512,000 美元，此前在该期间又购买了 413 股。CVA Family Office LLC 在第三季度将其在辉瑞的持股提高了 3.3%。CVA Family Office LLC 现在拥有 12,915 股辉瑞的股票，价值为 329,000 美元，此前在该期间又收购了 413 股。最后，Boltwood Capital Management 在第三季度将其在辉瑞的持股提高了 0.7%。Boltwood Capital Management 现在拥有 58,274 股辉瑞的股票，价值为 1,485,000 美元，此前在该期间又购买了 420 股。对冲基金和其他机构投资者持有该公司 68.36% 的股票。</p>
<h2>更多辉瑞新闻</h2>
<p>以下是本周影响辉瑞的主要新闻：</p>
<ul>
<li>积极情绪：第四季度业绩超预期和 GLP-1 顶线：辉瑞报告了收入和每股收益的上升，并发布了其主要 GLP-1 候选药物的积极二期 b 结果（强劲的安慰剂调整体重减轻），这提升了对新增长领域的情绪。辉瑞在第四季度业绩上升——但这可能是最重要的催化剂</li>
<li>积极情绪：管理层概述肥胖战略：辉瑞高管表示公司 “重返肥胖竞赛”，强调在鼓舞人心的 GLP-1 数据后，发展计划和商业化意图。健康回报：辉瑞高管在鼓舞人心的药物数据后制定肥胖战略</li>
<li>积极情绪：FDA 授予 HYMPAVZI sBLA 优先审查：该机构接受了一项补充生物制剂许可证申请，以扩大 HYMPAVZI 在儿童和血友病抑制剂人群中的适应症，如果获得批准，可能会扩大收入机会。FDA 授予 HYMPAVZI®（marstacimab）sBLA 优先审查</li>
<li>积极情绪：中期肥胖候选药物完成：辉瑞宣布完成 PF-07976016 的中期试验，增加了其 GLP-1/肥胖开发的节奏和潜在注册路径。辉瑞完成新肥胖药物候选 PF-07976016 的中期试验</li>
<li>积极情绪：管道与并购推动进入肿瘤学和肥胖领域：分析师和报道指出，辉瑞正在排定约 20 项关键研究，经过约 90 亿美元的 2025 年并购，依靠 Seagen 资产和 AI 工具加速研发——这是一个多年的增长故事。辉瑞在 2026 年管道推动中大力押注肥胖和肿瘤学</li>
<li>积极情绪：收入投资者关注：辉瑞出现在近期高收益股息股票名单上，这可能支持收益导向投资者的需求。3 只适合退休人员的高收益股息股票</li>
<li>中性情绪：成本节约/可负担计划：辉瑞推出了一项 TrumpRx 计划，提供约 30 种药物的折扣——对患者获取和公关有积极影响，但短期财务影响尚不明确。辉瑞推出 TrumpRx 成本节约计划</li>
<li>中性情绪：分析师观点混合：报道指出谨慎的上行——看涨的管道/AI 驱动因素与执行风险、商业化时间和 GLP-1 领域的竞争压力相平衡。辉瑞股票预测：分析师看到谨慎的上行</li>
<li>消极情绪：早期试验暂停：辉瑞暂停了 PF-07258669 在老年人中的早期研究，引入了可能需要调整计划的特定临床风险。辉瑞暂停 PF-07258669 在老年人中的早期试验</li>
</ul>
<h2>辉瑞股价上涨 2.8%</h2>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？该 ETF 包含它们所有</li>
</ul>
<p>辉瑞周五开盘价为 27.24 美元。该公司的 50 日移动平均线为 25.61 美元，200 日移动平均线为 25.10 美元。该公司的市值为 1548.8 亿美元，市盈率为 20.03，贝塔值为 0.47。辉瑞的 12 个月低点为 20.92 美元，12 个月高点为 27.69 美元。该公司的债务与股本比率为 0.62，速动比率为 0.97，流动比率为 1.28。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）最后一次发布季度财报是在 2 月 3 日，辉瑞报告该季度每股收益（EPS）为 0.66 美元，超出分析师一致预期的 0.57 美元，超出 0.09 美元。辉瑞的股本回报率为 20.25%，净利润率为 12.42%。该公司在该季度的收入为 175.6 亿美元，而一致预期为 169.3 亿美元。在去年同期，该公司每股收益为 0.63 美元。辉瑞的季度收入同比下降 1.2%。股票研究分析师预计辉瑞将在当前年度发布 2.95 美元的每股收益。</p>
<h2>辉瑞宣布分红</h2>
<ul>
<li>该 ETF 证明医疗行业复苏是真实的</li>
</ul>
<p>该公司最近宣布了季度股息，将于 3 月 6 日（星期五）支付。1 月 23 日（星期五）登记在册的股东将获得每股 0.43 美元的股息。这相当于年化 1.72 美元的股息，股息收益率为 6.3%。除息日期为 1 月 23 日（星期五）。辉瑞目前的股息支付比率为 126.47%。</p>
<h2>分析师评级调整</h2>
<p>PFE 已成为多份研究报告的主题。TD Cowen 在 12 月 30 日（星期二）的报告中重申了对辉瑞股票的 “持有” 评级。Sanford C. Bernstein 在 10 月 31 日（星期五）的报告中重申了 “市场表现” 评级，并设定了 30.00 美元的辉瑞股票目标价。Cantor Fitzgerald 在周三的报告中重申了 “中性” 评级，并对辉瑞股票设定了 27.00 美元的目标价。花旗集团在 12 月 2 日（星期二）开始对辉瑞股票进行覆盖，给予 “中性” 评级，并设定了 26.00 美元的目标价。最后，摩根士丹利在 11 月 5 日（星期三）的报告中重申了 “中性” 评级，并对辉瑞股票设定了 26.00 美元的目标价。一位分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，十二位给予 “持有” 评级，二位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价为 28.06 美元。</p>
<p><strong>查看我们对辉瑞的最新股票分析</strong></p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司（NYSE: PFE）是一家总部位于纽约市的跨国生物制药公司。公司成立于 1849 年，由查尔斯·辉瑞和查尔斯·厄哈特创立，专注于研究、开发、生产和商业化广泛的人类健康药物和疫苗。其活动涵盖发现研究、临床开发、监管事务、生产和全球商业分销，涉及多个治疗领域。</p>
<p>辉瑞的产品组合和研发管道涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及一个可观的疫苗业务。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>没有人谈论的购买狂潮</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
</ul>
<p><strong>想看看其他对 PFE 感兴趣的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

美国制药 ETF - iShares

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Alps Advisors Inc. 在第三季度将其在辉瑞公司（NYSE:PFE）的持股增加了 13.2%，目前持有 1,099,603 股，价值 2800 万美元。其他机构投资者也调整了他们的持股。辉瑞最近的第四季度积极业绩和肥胖药物管线的发展提升了投资者的信心。该公司正专注于扩大在肥胖和肿瘤领域的市场份额，同时推出节省成本的计划。然而，分析师的看法不一以及早期试验的暂停带来了一些风险</p>

<p>Alps Advisors Inc. grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 13.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 1,099,603 shares of the biopharmaceutical company's stock after acquiring an additional 128,134 shares during the quarter. Alps Advisors Inc.'s holdings in Pfizer were worth $28,018,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Alps Advisors Inc.最近向证券交易委员会提交的 13F 表格，该公司在 2023 年第三季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 13.2%。这家机构投资者在季度内额外收购了 128,134 股后，持有辉瑞的股票总数为 1,099,603 股。Alps Advisors Inc.在辉瑞的持股在最近一个季度末的价值为 28,018,000 美元。</p>
</div><ul>
<li>Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞在第四季度业绩上升——但这可能是最重要的催化剂</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Peak Asset Management LLC lifted its stake in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock worth $697,000 after purchasing an additional 402 shares during the last quarter. Community Bank &amp; Trust Waco Texas lifted its position in Pfizer by 0.6% in the 3rd quarter. Community Bank &amp; Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company's stock valued at $1,703,000 after purchasing an additional 412 shares during the last quarter. Able Wealth Management LLC boosted its position in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock worth $512,000 after buying an additional 413 shares during the period. CVA Family Office LLC boosted its position in Pfizer by 3.3% during the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company's stock worth $329,000 after acquiring an additional 413 shares during the period. Finally, Boltwood Capital Management lifted its holdings in Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company's stock worth $1,485,000 after purchasing an additional 420 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也增加或减少了在该公司的持股。Peak Asset Management LLC 在第二季度将其在辉瑞的持股提高了 1.4%。Peak Asset Management LLC 现在拥有 28,768 股辉瑞的股票，价值为 697,000 美元，此前在上个季度又购买了 402 股。Community Bank &amp; Trust Waco Texas 在第三季度将其在辉瑞的持股提高了 0.6%。Community Bank &amp; Trust Waco Texas 现在拥有 66,841 股辉瑞的股票，价值为 1,703,000 美元，此前在上个季度又购买了 412 股。Able Wealth Management LLC 在第二季度将其在辉瑞的持股提高了 2.0%。Able Wealth Management LLC 现在拥有 21,128 股辉瑞的股票，价值为 512,000 美元，此前在该期间又购买了 413 股。CVA Family Office LLC 在第三季度将其在辉瑞的持股提高了 3.3%。CVA Family Office LLC 现在拥有 12,915 股辉瑞的股票，价值为 329,000 美元，此前在该期间又收购了 413 股。最后，Boltwood Capital Management 在第三季度将其在辉瑞的持股提高了 0.7%。Boltwood Capital Management 现在拥有 58,274 股辉瑞的股票，价值为 1,485,000 美元，此前在该期间又购买了 420 股。对冲基金和其他机构投资者持有该公司 68.36% 的股票。</p>
</div><h2>More Pfizer News</h2>
<div class="lb-trans"><h2>更多辉瑞新闻</h2>
</div><p>Here are the key news stories impacting Pfizer this week:</p>
<div class="lb-trans"><p>以下是本周影响辉瑞的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most</li>
<li>Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is &#34;back in the obesity race,&#34; emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data</li>
<li>Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA</li>
<li>Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016</li>
<li>Positive Sentiment: Pipeline &amp; M&amp;A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&amp;A, leaning on Seagen assets and AI tools to accelerate R&amp;D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push</li>
<li>Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees</li>
<li>Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx</li>
<li>Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside</li>
<li>Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第四季度业绩超预期和 GLP-1 顶线：辉瑞报告了收入和每股收益的上升，并发布了其主要 GLP-1 候选药物的积极二期 b 结果（强劲的安慰剂调整体重减轻），这提升了对新增长领域的情绪。辉瑞在第四季度业绩上升——但这可能是最重要的催化剂</li>
<li>积极情绪：管理层概述肥胖战略：辉瑞高管表示公司 “重返肥胖竞赛”，强调在鼓舞人心的 GLP-1 数据后，发展计划和商业化意图。健康回报：辉瑞高管在鼓舞人心的药物数据后制定肥胖战略</li>
<li>积极情绪：FDA 授予 HYMPAVZI sBLA 优先审查：该机构接受了一项补充生物制剂许可证申请，以扩大 HYMPAVZI 在儿童和血友病抑制剂人群中的适应症，如果获得批准，可能会扩大收入机会。FDA 授予 HYMPAVZI®（marstacimab）sBLA 优先审查</li>
<li>积极情绪：中期肥胖候选药物完成：辉瑞宣布完成 PF-07976016 的中期试验，增加了其 GLP-1/肥胖开发的节奏和潜在注册路径。辉瑞完成新肥胖药物候选 PF-07976016 的中期试验</li>
<li>积极情绪：管道与并购推动进入肿瘤学和肥胖领域：分析师和报道指出，辉瑞正在排定约 20 项关键研究，经过约 90 亿美元的 2025 年并购，依靠 Seagen 资产和 AI 工具加速研发——这是一个多年的增长故事。辉瑞在 2026 年管道推动中大力押注肥胖和肿瘤学</li>
<li>积极情绪：收入投资者关注：辉瑞出现在近期高收益股息股票名单上，这可能支持收益导向投资者的需求。3 只适合退休人员的高收益股息股票</li>
<li>中性情绪：成本节约/可负担计划：辉瑞推出了一项 TrumpRx 计划，提供约 30 种药物的折扣——对患者获取和公关有积极影响，但短期财务影响尚不明确。辉瑞推出 TrumpRx 成本节约计划</li>
<li>中性情绪：分析师观点混合：报道指出谨慎的上行——看涨的管道/AI 驱动因素与执行风险、商业化时间和 GLP-1 领域的竞争压力相平衡。辉瑞股票预测：分析师看到谨慎的上行</li>
<li>消极情绪：早期试验暂停：辉瑞暂停了 PF-07258669 在老年人中的早期研究，引入了可能需要调整计划的特定临床风险。辉瑞暂停 PF-07258669 在老年人中的早期试验</li>
</ul>
</div><h2>Pfizer Trading Up 2.8%</h2>
<div class="lb-trans"><h2>辉瑞股价上涨 2.8%</h2>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？该 ETF 包含它们所有</li>
</ul>
</div><p>PFE opened at $27.24 on Friday. The firm's fifty day moving average is $25.61 and its two-hundred day moving average is $25.10. The firm has a market cap of $154.88 billion, a PE ratio of 20.03 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.</p>
<div class="lb-trans"><p>辉瑞周五开盘价为 27.24 美元。该公司的 50 日移动平均线为 25.61 美元，200 日移动平均线为 25.10 美元。该公司的市值为 1548.8 亿美元，市盈率为 20.03，贝塔值为 0.47。辉瑞的 12 个月低点为 20.92 美元，12 个月高点为 27.69 美元。该公司的债务与股本比率为 0.62，速动比率为 0.97，流动比率为 1.28。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the company earned $0.63 earnings per share. Pfizer's quarterly revenue was down 1.2% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最后一次发布季度财报是在 2 月 3 日，辉瑞报告该季度每股收益（EPS）为 0.66 美元，超出分析师一致预期的 0.57 美元，超出 0.09 美元。辉瑞的股本回报率为 20.25%，净利润率为 12.42%。该公司在该季度的收入为 175.6 亿美元，而一致预期为 169.3 亿美元。在去年同期，该公司每股收益为 0.63 美元。辉瑞的季度收入同比下降 1.2%。股票研究分析师预计辉瑞将在当前年度发布 2.95 美元的每股收益。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布分红</h2>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>该 ETF 证明医疗行业复苏是真实的</li>
</ul>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer's dividend payout ratio is presently 126.47%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 3 月 6 日（星期五）支付。1 月 23 日（星期五）登记在册的股东将获得每股 0.43 美元的股息。这相当于年化 1.72 美元的股息，股息收益率为 6.3%。除息日期为 1 月 23 日（星期五）。辉瑞目前的股息支付比率为 126.47%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>PFE has been the topic of a number of research reports. TD Cowen reiterated a &#34;hold&#34; rating on shares of Pfizer in a report on Tuesday, December 30th. Sanford C. Bernstein restated a &#34;market perform&#34; rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Cantor Fitzgerald restated a &#34;neutral&#34; rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a &#34;neutral&#34; rating and a $26.00 price objective for the company. Finally, The Goldman Sachs Group restated a &#34;neutral&#34; rating and issued a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $28.06.</p>
<div class="lb-trans"><p>PFE 已成为多份研究报告的主题。TD Cowen 在 12 月 30 日（星期二）的报告中重申了对辉瑞股票的 “持有” 评级。Sanford C. Bernstein 在 10 月 31 日（星期五）的报告中重申了 “市场表现” 评级，并设定了 30.00 美元的辉瑞股票目标价。Cantor Fitzgerald 在周三的报告中重申了 “中性” 评级，并对辉瑞股票设定了 27.00 美元的目标价。花旗集团在 12 月 2 日（星期二）开始对辉瑞股票进行覆盖，给予 “中性” 评级，并设定了 26.00 美元的目标价。最后，摩根士丹利在 11 月 5 日（星期三）的报告中重申了 “中性” 评级，并对辉瑞股票设定了 26.00 美元的目标价。一位分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，十二位给予 “持有” 评级，二位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价为 28.06 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Pfizer</strong></p>
<div class="lb-trans"><p><strong>查看我们对辉瑞的最新股票分析</strong></p>
</div><h2>Pfizer Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>辉瑞公司（NYSE: PFE）是一家总部位于纽约市的跨国生物制药公司。公司成立于 1849 年，由查尔斯·辉瑞和查尔斯·厄哈特创立，专注于研究、开发、生产和商业化广泛的人类健康药物和疫苗。其活动涵盖发现研究、临床开发、监管事务、生产和全球商业分销，涉及多个治疗领域。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>辉瑞的产品组合和研发管道涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及一个可观的疫苗业务。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The $650 Million Bet on AI's Future</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>The buying spree that no one is talking about</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>没有人谈论的购买狂潮</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 PFE 感兴趣的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Pfizer Inc. $PFE Shares Acquired by Alps Advisors Inc.

- Alps Advisors Inc. 增持 Pfizer 股票 13.2%，持有 1,099,603 股。  
- 利润报告超预期，季度收入达 175.6 亿美元，创下佳绩。  
- Pfizer 宣布 0.43 美元的季度股息，年化股息率为 6.3%。

Market Beat

医疗业 ETF - Vanguard

Alps Advisors Inc. 收购了辉瑞公司 $PFE 的股票